文献速递慢性静脉疾病

微粒化纯化黄酮类组分(MPFF)对新型慢性静脉高压实验模型的保护作用

Protective Effects of Micronized Purified Flavonoid Fraction (MPFF) on a Novel Experimental Model of Chronic Venous Hypertension.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2018-03-24

研究在仓鼠后肢慢性静脉高压模型上评估MPFF对微循环的保护作用,通过结扎股静脉分支或髂外静脉建立模型并给予MPFF、MPFF伴生活性黄酮、地奥司明或溶媒。结果显示MPFF较地奥司明更有效改善全部微血管指标,其优势可能源于地奥司明与MPFF活性黄酮的协同作用。

要点

  • A+B+C和D结扎模型在结扎后第2至10周出现浅表静脉压进行性升高及微循环显著改变。
  • D模型显著升高浅表静脉压而不影响中心静脉压,故用于评估长期药物治疗效果。
  • 与溶媒相比,MPFF、MPFF伴生活性黄酮及地奥司明均显著减少白细胞-内皮相互作用并防止功能性毛细血管密度下降。

核心结论

  • MPFF在改善全部微血管指标方面比单用地奥司明更有效,其优势可由地奥司明与MPFF活性黄酮联用的协同有益作用解释。

研究设计与样本

  • 在雄性仓鼠上实施静脉结扎建立慢性后肢静脉高压低血流模型,分组包括A(右股静脉)、A+B(右股静脉及其右支)、A+C(右股静脉及其左支)、A+B+C(右股静脉及其左右支)、D(右髂外静脉),并设仅行血管分离而不结扎的假手术组。

主要发现

  • A、A+B和A+C模型通过侧支维持静脉回流。
  • 结扎后第2至10周,A+B+C模型浅表静脉压从3.83 ± 0.65 mmHg升至8.56 ± 0.72 mmHg(p < .001),D模型从4.13 ± 0.65 mmHg升至9.35 ± 0.65 mmHg(p < .001),并伴微循环显著改变。
  • D模型显著升高浅表静脉压而不影响中心静脉压。
  • 与溶媒相比,MPFF、MPFF伴生活性黄酮及地奥司明均显著减少白细胞-内皮相互作用并防止功能性毛细血管密度下降。
  • 仅MPFF显著防止溶媒治疗组所见的微静脉扩张。

关键数值与推荐

  • MPFF以100 mg/kg口服,MPFF伴生活性黄酮(地奥司明、橙皮苷、蒙花苷和异绣线菊苷)以10 mg/kg口服,地奥司明以100 mg/kg口服,溶媒对照,均于静脉结扎前2周及结扎后6周给药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess protective effects of micronized purified flavonoid fraction (MPFF) on microcirculation in an original chronic model of hind limb venous hypertension with low blood flow in small animals. METHODS: Vein ligatures were performed on male hamsters, as follows: A-right femoral vein; A + B-right femoral vein and its right branch; A + C-right femoral vein and its left branch; A + B + C-right femoral and its right and left branches; D-external right iliac vein. In sham operated groups, similar vascular dissections were performed without ligatures. Superficial (epigastric) and central (jugular) venous pressure evaluations were made during a 10 week period. Hamsters subjected to A + B + C and D ligatures were selected for leukocyte rolling and sticking, functional capillary density (FCD), and venular and arteriolar diameter observations. D ligature was selected to evaluate pharmacological treatment efficacy. MPFF (100 mg/kg), concomitant active flavonoids of MPFF (diosmetin, hesperidin, linarin, and isorhoifolin) (10 mg/kg), diosmin (100 mg/kg) or drug vehicle were administered orally during 2 weeks before vein ligature and 6 weeks thereafter. RESULTS: A, A + B and A + C models maintained venous return through collaterals. From the 2nd to the 10th weeks after vein ligatures, A + B + C and D models elicited a progressive increase of superficial venous pressure (3.83 ± 0.65 vs. 8.56 ± 0.72 mmHg, p < .001 and 4.13 ± 0.65 vs. 9.35 ± 0.65 mmHg, p < .001, respectively) with significant changes to the microcirculation. As D model significantly increased superficial venous pressure without affecting central venous pressure, it was used to evaluate the long-term effects of treatment. Compared with vehicle, MPFF, concomitant active flavonoids of MPFF, and diosmin, significantly decreased leukocyte-endothelium interaction and prevented FCD reduction. Only MPFF significantly prevented venular enlargement as observed in the vehicle treated group. CONCLUSION: MPFF was more effective than diosmin in improving all microvascular variables. The superiority of MPFF over diosmin alone can be explained by the synergistic beneficial effects of the association between diosmin and active flavonoids of MPFF.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. das Graças C de Souza M, Cyrino FZ, de Carvalho JJ, et al. Protective Effects of Micronized Purified Flavonoid Fraction (MPFF) on a Novel Experimental Model of Chronic Venous Hypertension. Eur J Vasc Endovasc Surg. 2018. PMID: 29588131. doi:10.1016/j.ejvs.2018.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。